User:Mr. Ibrahem/Omega-3 acid ethyl esters

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Omega-3 acid ethyl esters
Chemical structure of ethyl eicosapentaenoate, an important omega-3 acid ethyl ester
Combination of
Eicosapentaenoic acidAntilipemic agent
Docosahexaenoic acidAntilipemic agent
Clinical data
Trade namesLovaza, Omtryg, others
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classOmega-3 fatty acid
Legal status
Legal status
  • UK: POM (Prescription only)[2]
  • US: ℞-only
  • In general: ℞ (Prescription only)

Omega-3 acid ethyl esters are the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish oil.[3] Together with dietary changes, they are used to treat high blood triglycerides which may reduce the risk of pancreatitis.[3][6] They are generally less preferred than statins and use is not recommended by NHS Scotland as the evidence does not support a decreased risk of heart disease.[3][4][7] Omega-3 acid ethyl esters are taken by mouth.[3]

Common side effects include burping, nausea, and an upset abdomen.[3][4] Serious side effects may include liver problems and anaphylaxis.[3] While use in pregnancy has not been well studied, some omega-3 fatty acids appear beneficial.[1] How it works is not entirely clear.[3]

Omega-3 acid ethyl ester medicines were approved for medical use in the European Union in 2000, and in the United States in 2004.[7][8][3] It is available as a generic medication and over the counter.[4][3] A one-month supply in the United Kingdom costs the NHS about £6 as of 2019.[4] In the United States the wholesale cost of this amount is about 7.50 USD.[9] In 2017, it was the 158th most commonly prescribed medication in the United States, with more than three million prescriptions.[10][11]

References[edit]

  1. ^ a b c "Omega-3 polyunsaturated fatty acids Use During Pregnancy". Drugs.com. Archived from the original on 13 April 2019. Retrieved 13 April 2019.
  2. ^ "Summary of Product Characteristics (SmPC) - (emc)". Omacor. 11 December 2019. Archived from the original on 13 August 2019. Retrieved 15 May 2020.
  3. ^ a b c d e f g h i j k "Omega-3-acid Ethyl Esters Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 13 April 2019. Retrieved 13 April 2019.
  4. ^ a b c d e British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 206–207. ISBN 9780857113382.
  5. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 9 September 2020.
  6. ^ Karalis DG (February 2017). "A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids". Advances in Therapy. 34 (2): 300–323. doi:10.1007/s12325-016-0462-y. PMC 5331085. PMID 27981496.
  7. ^ a b "Omega-3 fatty acid medicines". European Medicines Agency. 17 September 2018. Archived from the original on 13 April 2019. Retrieved 13 April 2019.
  8. ^ "Drug Approval Package: Omacor (Omega-3-Acid Ethyl Esters) NDA #021654". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 2 February 2020. Retrieved 15 May 2020.
  9. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
  10. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  11. ^ "Omega-3-acid Ethyl Esters - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Omega-3_acid_ethyl_esters&oldid=1212949823"